Business Context and Reporting Period
Profound Medical Corp. (PROF), a Canadian company incorporated in Ontario, filed a Form 8-K Current Report dated December 30, 2025. The filing reports the closing of a private placement offering of common shares to certain Canadian investors.
Key Financial Metrics
- Capital Raised: Aggregate gross proceeds of $6.45 million.
- Shares Issued: 921,428 common shares.
- Offering Price: $7.00 per share.
- Liquidity Impact: Immediate cash inflow from the closed offering; specific pre-offering cash balances or debt levels are not disclosed in this filing.
- Revenue/Profit: Not applicable; this filing does not contain operational financial results.
Material Changes
The primary material change is the increase in equity capital and share count resulting from the private placement. The offering was executed under Regulation S of the Securities Act of 1933, involving non-U.S. persons outside the United States. The shares are subject to transfer restrictions and cannot be sold in the U.S. absent registration or an applicable exemption.
Outlook, Risks, and Management Commentary
- Registration Intent: The Company intends to file a registration statement for the resale of the Shares within four months of the closing date.
- Legal Framework: The transaction relied on exemptions from registration; the Subscription Agreement contains customary representations, warranties, and covenants.
- Disclosure Status: A press release announcing the closing was issued on December 30, 2025, and is furnished as Exhibit 99.1. This information is not deemed "filed" for liability purposes under the Exchange Act.
Investor Verification Checklist
- Verify the exact number of shares issued (921,428) and the total gross proceeds ($6.45 million) against the company's subsequent 10-K or 10-Q filings.
- Confirm the timeline for the filing of the resale registration statement (expected within four months of December 30, 2025).
- Review the full text of the Subscription Agreement (Exhibit 10.1) for specific covenants or conditions attached to the investment.
- Monitor the press release (Exhibit 99.1) for any additional details on the intended use of proceeds not explicitly detailed in the 8-K summary.